SURVEY SAYS— Payer Perspectives on Gene Therapy Reimbursement Results and analysis of the second of two surveys conducted by the FoCUS Project to reveal present payer perspectives regarding current and future … Read More
FoCUS Project teams with the National Pharmaceutical Council (NPC) to explore Medicaid Best Price reforms
FoCUS and NPC plan to explore Medicaid Best Price reforms required to enable precision financing solutions, including analyzing potential adverse effects on Medicaid. The research will combine a review of … Read More
Payer Perspectives on Gene Therapy Reimbursement
J.F. Barlow; M.W. Courtney; M. Trusheim. Pharmaceutical Executive, 04/2020 The reimbursement of emerging durable and potentially curative cell and gene therapies challenge US payers due to their high upfront costs. … Read More
FoCUS Monthly Recap: March 2020
RECAP Paying for Cures Workshop explores challenges faced by payers, and innovative solutions FoCUS held its second Paying for Cures Workshop at MIT, this one focused on the challenges payers … Read More
Adaptive Reimbursement Innovation Unites NEWDIGS’s FoCUS and LEAPS Projects
Systems approach to biomedical innovation enables improved access for patients. FoCUS’s Precision Financing Solutions for durable cell and gene therapies and the LEAPS’s learning ecosystem to optimize therapeutic regimens for … Read More
Paying for Cures Workshop explores challenges faced by payers, and innovative solutions
FoCUS held its second Paying for Cures Workshop at MIT on March 10, this one focused on the challenges payers face when considering new cell and gene therapies. The attendees … Read More
FoCUS Monthly Recap: February 2020
NOW ONLINEPaying for Cures ToolkitResearch, strategies, and do-it-yourself analysis tools will help you understand the potential impact of new therapies and plan for practice and policy innovation. Visit the Toolkit SOLD OUTPaying … Read More
FoCUS Monthly Recap: January 2020
Registration Open: Paying for Cures Workshop March 10 at MITSurvey the financial challenges of sustaining new cell and gene therapies, assess adoption barriers, and anticipate coming changes in practice and … Read More
Impact of FDA Guidelines on Communication between Developers and Payers on Metrics in Performance-Based Agreements
The FDA regulates communications from pharmaceutical developers to ensure that statements about products are appropriately supported by evidence. In this Research Brief, we explore the possible impacts of these regulations … Read More
Payer Perspectives on Reimbursement of One-Time High-Cost Durable Therapies
Jane F. Barlow, Matt W. Courtney, and Mark Trusheim of the FoCUS Project contributed the article to PharmExec.com, published January 9, 2020. The reimbursement of emerging durable and potentially curative … Read More